Thalia Therapeutics PLC THAT

Thalia Therapeutics (AIM:THAT) CEO Dr David Solomon joined Proactive's Stephen Gunnion to discuss the acquisition of Sanmirna Therapeutics and how it transforms Thalia into a clinical-stage RNA therapeutics business. The deal brings clinical-stage asset miRisten into Thalia's portfolio, adding a Phase 1 trial currently recruiting AML patients at City of Hope. miRisten targets miR-126, a microRNA associated with disease progression. Solomon explained that reducing it may slow AML while making leukaemia stem cells more susceptible to existing treatments such as Venetoclax and chemotherapy. The a

Acquisition of oncology company Sanmirna Therapeutics Inc for its clinical-stage Acute Myeloid Leukaemia RNA therapy Acquisition catapults Thalia to a clinical-stage RNA therapeutics company and is expected to be fundamentally value accretive Advances ...